Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

34.5%

10 terminated/withdrawn out of 29 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

17 recruiting9 terminated

Enrollment Performance

Analytics

Early Phase 1

10(34.5%)

Phase 1

9(31.0%)

N/A

9(31.0%)

Phase 2

1(3.4%)

29Total

Early Phase 1(10)

Phase 1(9)

N/A(9)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT06077903Early Phase 1Terminated

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Role: lead

NCT06094426Early Phase 1Terminated

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

Role: lead

NCT06145802Not ApplicableWithdrawn

Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)

Role: lead

NCT06191900Not ApplicableTerminated

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Role: lead

NCT06519669Not ApplicableTerminated

Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer

Role: lead

NCT06235242Not ApplicableTerminated

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Role: lead

NCT06834542Early Phase 1Terminated

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors

Role: lead

NCT05430360Phase 1Terminated

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Role: lead

NCT05729399Phase 1Terminated

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Role: lead

NCT06144671Phase 1Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

Role: lead

NCT06190275Not ApplicableRecruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Role: lead

NCT07205315Early Phase 1Recruiting

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Role: lead

NCT07389499Early Phase 1Not Yet Recruiting

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

Role: lead

NCT06491225Phase 1Terminated

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma

Role: lead

NCT07534813Not ApplicableNot Yet Recruiting

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

Role: lead

NCT07132112Early Phase 1Recruiting

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

Role: lead

NCT06241781Phase 2Recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Role: lead

NCT06453057Not ApplicableRecruiting

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

Role: lead

NCT06819293Phase 1Recruiting

IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma